2266 Sex and their Modulators

sufficient to cause distress, has been described in a woman Preparations and is mainly excreted as peptide fragments in the faeces. given for mastalgia. The improved after About 20 to 30% of a dose is renally excreted. Degarelix is stopping the danazol.' ProprietaryPreparations (details are given in Volume B) injected to form a subcutaneous depot, and the I. Gately LE, Andes WA. Danazol and erythema multiforrne. Ann Intern Single-ingredient Preparations. Arg.: Ladoga!; Austral.: Azol; of the drug is strongly Influenced by the Med 1988; 109: 85. Danocrinet; : Danokrin; Belg.: Danatrol; Braz.: Ladogal; concentration of the injected solution. After subcutaneous 2. Reynolds NJ, Sansom JE. Erythema multiforme during danazol therapy. Canad. : Cyclamen; China: Gong Fu Yi Kang (:g;ffl!jj>�); Cz. : injection of 240 mg at a concentration of 40 mg/mL, Clin Exp Dermato/ 1992; 17: 140. 3. Zawar V, Sankalecha C. Facial hirsutism following danazol therapy. Cutis Danoval; Fr.: Danatrol; Gr.: Danatrol; Hong Kong: Anargil; degarelix has a terminal half-life of about 43 to 53 days; after 2004; 74: 301-3. Azolt; Danocrine; Hung.: Danoval; : Benzol; Danogen; maintenance doses of 80 mg as 20 mg/mL the half-life is Endozol; Gonablok; Gynadom; Gynazol; Gynodan; Ladoga!; about 28 days. Zendol; Indon.: Azol; Danocrine; Irl.: Danolt; Israel: Danol; Precautions Ital.: Danatrol; Jpn: Bonzol; Malaysia: Anargil; Azolt; Ladogal; Preparat ons Nazol; Mex. : Danalem; Ladogal; Novaprin; Neth.: Danatrol; NZ: i . Danazol should be used with caution in conditions that may ······························· ...... Azol; D-Zolt; Philipp.: Ladoga!; Port. : Danatrol; Rus.: Danol ProprietaryPreparations (details are given in Volume B) be adversely affected by fluid retention, such as in (,!\aHon); Danoval (,!\aHoBaJJ); S.Afr. : Danogen; Ladazol; Singa­ Austral.: Firmagon; Austria: Fir­ cardiovascular, hepatic, and renal disorders; it should be pore: Azolt; Ladoga!; Nazol; Spain: Danatrol; Switz. : Danatrolt; Single-ingredient Preparations. magon; Belg.: Firmagon; Canad. : Firmagon; Cz.: Firmagon; avoided in marked dysfunction. It should also be used with Thai.: Anargil; Ectopal; Ladogal; Vabon; Turk. : Danasin; UK: Denm.: Firmagon; Fr.: Firmagon; Ger.: Firmagon; Gr.: Firma­ care in patients with mellitus, polycythaemia, Danol; Venez.: Danogen; Ladoga!. abnormal , , or epilepsy. Danazol gon; Irl. : Firmagon; Israel: Firmagon; Jpn: Gonax; Neth.: Fir­ magon; Norw.: Firmagon; Pol.: Firmagon; Port.: Finnagon; should not be given to patients with undiagnosed genital PharmacopoeialPreparations USP 36: Danazol Capsules. Swed. : Firmagon; Switz. : Firmagon; UK: Firmagon; USA: Fir­ bleeding or -dependent tumours. As with other magon. 17a-alkylated compounds, there is an increased risk of disorders and liver function should be monitored during therapy. It should not be used in patients with a thromboembolic disorder or a history of . Danazol should not be given during because of a possible androgenic effect on the female (see below), and non- is recommended during treatment. Caution is required in children and adolescents since precocious sexual development may occur in boys and virilisation in girls, and premature epiphyseal closure may occur in both sexes. In the event of androgenic effects, danazol should be withdrawn, as they may prove irreversible on continued use.

Breast feeding. Licensed product information warns that danazol should be avoided in breast-feeding women because of the theoretical potential for androgenic effects in the infant. is a with anti-androgenic and anti-oestrogenic activity. It is used as an anti-androgen Porphyria. The Drug Database for Acute Porphyria, com­ in veterinary practice. piled by the Norwegian Porphyria Centre (NAPOS) and the Porphyria Centre Sweden, classifies danazol as prob­ ably porphyrinogenic; it should be prescribed only for compelling reasons and precautions should be considered in all patients 1 L The Drug Database for Acute Porphyria. Available at: http://www. drugs-porphyria.org {accessed 06/10/11)

Pregnancy. Reports of masculinisation of female infants Uses and Administration born to mothers who had received danazol during Like (p. 2257.2), degarelix is a gonadorelin pregnancy.1-3 (gonadotrophin-releasing ) antagonist. It is used to I. Shaw RW, Farquhar JW. Female pseudohermaphroditism associated reduce concentrations in the hormonal therapy with danazol exposure in utero: case report. Br J Obstet Gynaecol l984; 91: of advanced prostate cancer (p. 712.3 ). Degarelix is given as 386-9. the acetate, but doses are expressed in terms of the base. It is 2. Kingsbury AC. Danazol and fetal masculinization: a warning. Med J Aust 1985; 143: 410-1 1. given as a subcutaneous depot injection in the abdominal 3. Brunskill PJ. The effects of fetal exposure to danazol. Br J Obstet Gynaecol area. An initial dose of degarelix 240 mg is given in two Deslorelin is an analogue of gonadorelin (p. 2280.2) that has 1992; 99: 212-1 5. separate injections of 120 mg, as a solution of 40 mg/mL. been investigated in the treatment of precocious puberty, Maintenance doses of 80 mg are then given once every 28 short stature, prostate cancer, and . days, as a solution of 20 mg/mL. References. Interactions I. Anonymous. Deslorelin: D-Trp-LHRH-PEA, LHRH analogue, Therapy with danazol may inhibit the hepatic of Van Poppel H, et a!. Degarelix: a novel -releasing hormone Somagard. Drugs R D 1999; 2: 420-2. several drugs including (see p. 517.3), (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, 2. Klein KO, et al. Increased final height in precocious puberty aher long­ term treatment with LHRH : the National Institutes of Health (see below), and possibly tacrolirnus (see phase 2 dosage-finding study in the treatment of prostate cancer. Bur Urol 2008; 54: 805-13. experience. J Clin Endocrinol Metab 2001; 86: 471 1-16. p. 1973.2). Danazol may also enhance the effects of warfarin 2. Gittelman M, et a!. Degarelix Study Group. A 1-year, open label, 3. Yanovski JA, et al. Treatment with a -releasing (see Sex Hormones under Warfarin, p. 1535.1). Introduc­ randomized phase II dose finding study of degarelix for the treatment of hormone agonist in adolescents with short stature. N Engl J Med 2003; 348: tion of danazol appeared to reduce the maintenance prostate cancer in North America. J Urol (Baltimore) 2008; 180: 1986-92. 908-17. 4. Weise M, et a!. Determinants of growth during gonadotropin-releasing requirement for alfacalcidol (see p. 2118.1). Rhabdomyo­ 3. Klotz L, et al. The efficacy and safety of dcgarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in hormone analog therapy for precocious puberty. J Clin Endocrinol Metab Iysis has been attributed to use of danazol with statins (see patients with prostate cancer. BJU Int 2008; 102: 1531-8. 2004; 89: 103-7. p. 1495.2). 4. Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs 2009; 69 1967- : 76. 5. Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist Ciclosporin. Danazol may raise ciclosporin concentrations for the management of prostate cancer. Clin Ther 2009; 31: 2312-3 1. (see p. 1955.1), possibly by inhibiting its metabolism. A case of fatal acute hepatic failure due to centrilobular massive hepatic necrosis was attributed to danazol in a Adverse Effects and Precautions patient already taking ciclosporin.1 Danazol may have raised Injection site reactions of pain and erythema are very the ciclosporin concentrations in this case, but the authors common with degarelix, while swelling, induration, and speculated that an alternative interaction between the two nodules occur less often but may still be common. Transient drugs might have played a role in this reaction to danazol. chills, fever, and flu-like symptoms may occur hours after 1. Hayashi T, et a!. Fatal acute hepatic failure induced by danazol in a dosing. Other effects commonly reported for degarelix have patient with endometriosis and aplastic anemia. J Gastroenterol2001; 36: included increases in liver values, insomnia, 783-6. dizziness, , and gastrointestinal disturbances. Hot flushes are a very common consequence of androgen Pharmacokinetics suppression by degarelix, while night sweats, , and weight gain are common complaints. Degarelix can also Ph. Eur. 8: (). A white or almost white, Danazol is absorbed from the and contribute to loss of libido, erectile dysfunction, testicular crystalline powder. Practically insoluble in water; freely metabolised in the liver; absorption is markedly increased if atrophy, and gynaecomastia. Long-term androgen depriva­ soluble in dehydrated alcohol and in dichloromethane; very it is taken with food. A plasma elimination half-life of 3 to 6 tion therapy in general has also been associated with soluble in methyl alcohol. hours has been reported after a single dose, but is increased prolongation of the QT interval and decreases in bone to about 26 hours with repeated dosing. , 2- density. hydroxymethylethisterone, and I 7 -hydroxymethylethis­ Uses and Administration terone are the major metabolites, though none have Desogestrel is a progestogen (see . p. 2300.2) pituitary inhibiting activity. Danazol and its metabolites Pharmacokinetics structurally related to that is used as a may undergo enterohepatic circulation. Metabolites are Degarelix is about 90% bound to plasma proteins. It hormonal contraceptive (see p. 2231.3). A typical daily dose excreted in the and faeces. undergoes peptide hydrolysis in the hepato-biliary system, of 150 micrograms is used as the progestogenic component

All cross-references refer to entries in Volume A 2267

of monophasic combined oral contraceptive preparations. ette; Gr. : Cerazette; Hong Kong: Cerazette; Hung. : Azalia; Cer­ Doses of 50 to 150 micrograms daily may be used in triphasic azette; India: Cerazette; Indon.: Cerazette; Irl. : Cerazette; combined preparations. A dose of 75 micrograms daily is Israel: Cerazette; Ital.: Cerazet; Cerazette; Mex.: Cerazette; used as an oral progestogen -only contraceptive; unlike Neth.: Cerazette; Norw.: Cerazette; NZ: Cerazette; Philipp.: traditional progestogen-only contraceptives, desogestrel is Cerazette; Pol.: Azalia; Cerazette; Port.: Cerazette; Rus.: Ceraz­ ('lap03erra); (JlaKTHHer); Spain: said to reliably inhibit . Progestogen-only ette Lactinette Azalia; Cerazet; Swed.: Cerazette; Switz. : Cerazette; Thai.: Cerazette; UK: contraceptive efficacy is reduced if a dose of desogestrel is Aizea; Cerazette; Cerelle; Zelleta; Ukr.: Cerazette (qapo3erra); is a nonethinylated progestogen (see Progester­ delayed by more than 12 hours. Lactinette (JlaK.TnHer); Venez.: Arlette; Cerazette. one, p. 2300.2) structurally related to nortestosterone. It is reported to have anti-androgenic properties. Dienogest is The effects of a progestogen-only Arg.: Aus­ Contraception. Multi-ingredient Preparations. Marvelon; Mercilon; used as the progestogen component of some combined oral contraceptive containing desogestrel have been tral. : Marvelon; Austria: Gracial; Liberel; Marvelon; Mercilon; contraceptives (see p. 2231.3). A dose of 2mg daily is reported.1·3 Oral desogestrel has also been investigated as Belg.: Desorellet; Gracial; Marvelon; Mercilon; Ovidol; Braz.: typically used in monophasic preparations, and doses of 2 or a , combined with testosterone given Femina; Gestradiol; Gracia]; Malu; Mercilon Conti; Merdlon; 3 mg daily may be found in multiphasic sequential by ,4 subcutaneous implant,5•6 or Microdiol; Minian; Novial; Primera; Primeravintet; Canad. : preparations. It is also used as the progestogen component transdermal patch.7 Apri; Linessa; Marvelon; Ortho-Cept; Chile: Ciclidon; Conti­ Marvelon; Dal; Desoren; Gracial; Gynostat; Marvelon; Midalet; in menopausal HRT (see p. 2244. 1) in a daily dose of 2 mg. l. Collaborative study group on the desogestrel-containing progestogen­ (�JlXJk); In the management of endometriosis (p. 2264.1) an oral only pill. A double-blind study comparing the contraceptive efficacy, Miniestrel; Neolette; China: Mercilon Cz.: Adele; Gra­ acceptability and safety of two progestogen-only pills containing cial; Laurina; Marvelon; Mercilon; Natalya; Novynette; Regu­ dose of dienogest 2 mg daily is used; it is given in a desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. lon; Tricia; Denm.: Daisynelle; Desorelle; Femelle; Femigen; continuous regimen regardless of menstrual bleeding. Bur J Contracept Reprod Health Care 1998; 3: 169-78. Femistad; Gracial; Marvelon; Mercilon; Novynette; Fin.: Gra­ Reviews. 2. Rice CF, et al. A comparison of the inhibition of ovulation achieved by cial; Laurina; Marvelon; Mercilon; Fr.: Cycleanet; Desobel; l. Foster RH, Wilde Dienogest. Drugs 1998; 56: 825-33. desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum MI. Mercilon; Varnoline; Ger.: Biviol; Cyclosat; Desmin; Lamunat; 2. Wellington Perry CM. valerate/dienogest. Drugs 2002; 62: Reprod 1999; 14: 982-5. K 491-504. 3. Korver T, et al. Maintenance of ovulation inhibition with the 75- Lavelle; Marvelon; Novial; Oviala; Oviolt; Gr.: Gracial; Lauri­ 3. Hoy SM, Scott LJ. /dienogest: in oral contraception. microgram desogestrel-only contraceptive pill (Cerazette) after na; Marvelon; Mercilon; Hong Kong: Gracial; Marvelon; Drugs 2009; 69: 1635--46. scheduled 12-h delays in tablet intake. Contraception 2005; 71: 8-13. Mercilon; Novynette; Hung.: Gracial; Laurina; Marvelon; 4. Perez-Campos EF. Ethinylestradioltdienogest in oral contraception. 4. Wu FCW, et al. Oral progestogen combined with testosterone as a Mercilon; Novynette; Regulon; Samba; India: Femilon; Locipil; Drugs 2010; 70: 681-9. potential male contraceptive: additive effects between desogestrel and Novelon; Indon.: Marvelon; Mercilon; Irl. : Gracial; Leticia; 5. McCormack PL. Dienogest: a review of its use in the treatment of te<;;tosterone enanthate in suppression of spermatogenesis, pituitary­ Marviol; Mercilon; Vivides; Israel: Feminet; Mercilon; 1\tticro­ endometriosis. Drugs 2010; 70: 2073-88. testicular axis, and . J Clin Endocrinol Metab 1999; 84: 112-22. diol; Ital. : Dueva; Gracial; Lucille; Mercilon; Novynette; Pla­ 5. Kinniburgh D, et al. Oral desogestrel with testosterone pellets induces num; Practil; Securgin; Malaysia: Marvelon; Merdlon; Novyn­ Porphyria. The Drug Database for Acute Porphyria, com­ consistent suppression of spermatogenesis to in both ette; Regulon; Mex. : Desmin; Detegen; Marvelon; Mercilon; piled by the Norwegian Porphyria Centre (NAPOS) and Caucasian and Chinese men. Hum Reprod 2002; 17: 1490-1501. Novial; Neth.: Gracial; Juliane; Laurina; Lonicera; Marvelon; the Porphyria Centre Sweden, classifies dienogest and oes­ 6. Anderson RA, et al. Investigation of hormonal male contraception in Norw.: NZ: Mercilon; Ovidolt; Marvelon; Mercilon; Marvelon; trogen combinations as probably porphyrinogenic; it African men: suppression of spermatogenesis by oral desogestrel with Mercilon; Philipp.: Gracia!; Marvelon; Mercilon; Pol.: depot testosterone. Hum Reprod 2002; 17: 2869-77. should be prescribed only for compelling reasons and pre­ Marvelon; Mercilon; Novynette; Regulon; Port.: Gracial; Lauri­ 7. Hair WM, et a!. A novel male contraceptive pill-patch combination: oral cautions should be considered in all patients.' desogestrel and transdermal testosterone in the suppression of na; Marvelon; Mercilon; Novynette; Regulon; Rus.: Marvelon l. The Drug Database for Acute Porphyria. Available at: http:l/www. spermatogenesis in normal men. J Clin Endocrinol Metab 2001; 86: (MapnenoH); Mercilon (MepcHJioH); Novynette (HonHHer); Regu­ drugs-porphyria.org (accessed 04/lO/ll) '5201-9. lon (PerynoH); Tri-Merci (Tpw-Mepca); S.Afr.: Marvelon; Mercilon; Singapore: Marvelon; Mercilon; Spain: Bemasive; Swed. : Gracial; Microdiol; Regulon; Suavuret; Desolett; P.r.�P.?.r<:lti()n.� ...... Adverse Effects and Precautions Switz. : Mercilon; Trimiront; Desoren; Gracia!; Marvelon; (details are given in Volume B) As for in general (see Progesterone, p. 2301.2 Mercilon; Thai.: Daisy; Marvelon; Mercilon; Minny; Novyn­ ProprietaryPreparations and p. 2301.3). See also under Hormonal Contraceptives, ette; Oilezz; Turk. : Desolett; Myralon; UK: Cimizt; Gedarel; Single-ingredient Prepara�ons. Austral.: Visanne; Austria: p. 2233.3 and p. 2240.3. When used as a progestogen-only Marvelon; Mercilon; Ukr.: Marvelon (MapnenoH); Mercilon Visanne; Canad.: Visanne; Cz.: Visanne; Denm.: Visanne; Fin.: contraceptive, irregular bleeding is more common with (MepcmiOH); Novynette (HonHHer); Regulon (PerynoH); Tri­ Visanne; Ger.: Visanne; Gr.: Visannette; Hung.: Visanne; Israel: desogestrel than with other progestogen-only preparations. Merci (TpH-MepcH); USA: Apri; Azurette; Caziant; Cesia; Visabelle; Jpn: Dinagest; Neth.: Visanne; Norw.: Visanne; Port. : Desogestrel is reported to have few androgenic effects, and Cyclessa; Desogen; Kariva; Mircette; Ortho-Cept; Reclipsen; Visanne; Singapore: Visanne; Spain: Visannette; Swed.: to have less adverse effect on the serum lipid profile than Solia; Velivet; Viorele; Venez. : Ciclidon; Marvelon; Mercilon; Visanne; Switz. : Visanne. Mipil; Novial. older 19-nortestosterone derivatives. However, there is Multi-ingredient Prepara�ons. Arg.: Dienopil; Florence; Rubi; some evidence that desogestrel-containing combined oral PharmacopoeialPrepara�ons Austral.: Qlaira; Valette; Austria: Motion; Qlaira; Valette; Belg.: contraceptives are associated with a small increased risk of BP 2014: Desogestrel Tablets; Climodien; Qlaira; Chile: Gianda; Tinelle; Cz. : Dienille; Dienor­ venous thromboembolism (see p. 2238.1, and for USP 36: Desogestrel and Ethinyl Estradiol Tablets. ette; Jeanine; Klimodien; Qlaira; Denm.: Climodient; Qlaira; precautions, see p. 2241.2). Fin.: Qlaira; Fr.: Climodiene; Qlaira; Ger.: Climodien; Lafarnme; Maxim; Qlaira; Valette; Gr.: Climodien; Qlaira; Porphyria. The Drug Database for Acute Porphyria, com­ Hung. : Dienille; Qlaira; Irl.: Qlaira; Israel: Qlair; Ital. : Klaira; piled by the Norwegian Porphyria Centre (NAPOS) and Neth.: Climodien; Lafamme; Qlaira; Norw.: Climodient; Qlaira; the Porphyria Centre Sweden, classifies desogestrel in Pol.: Atywia; Jeanine; Qlaira; Port. : Climodien; Lafamme; combined hormonal contraceptives as probably porphyri­ Qlaira; Valette; Rus.: Climodien (KnHMO.rt:HeH); Jeanine ()KaHHH); nogenic; it should be prescribed only for compelling rea­ Singapore: Qlaira; Spain: Ailyn; Climodien; Danielle; Donabel; sons and precautions should be considered in all patients.1 Mevaren; Qlaira; Swed. : Climodient; Qlaira; Turk.: Climodien; UK: Qlaira; Ukr.: Jeanine ()KaHHH); Klimodien (KrrHMO,D.JfeH)t; l. The Drug Database for Acute Porphyria. Available at: http:/fwww. Silhouette (CJIJIYeT); USA: Natazia. drugs-porphyria.org (accessed 04/ 10111) Interactions (BAN, r/NN) As for progestogens in general (see Progesterone, p. 2302.2). See also under Hormonal Contraceptives, p. 2242.3. [)ES: Diethylstilbestrol; D!ethylstilb¢sttiotu•n:· •. oJeth)dliti!boes" trol; . Dietilestii!JE:srtol: • Dietilstlfbest.tolis: .• ()ietil�tiii;Qsztrol; Oi�;.tylstiltl strol; Oi�tyyllstlfbestroH; Es ilb!!strol; NSC -3010: Pharmacokinetics USP 36: (). Colourless, white, or practically white ; .• � Stilb�?'!01; tilboestrof; After oral doses, desogestrel undergoes oxidative transfor­ needle-like crystals, or white or practically white crystalline � )lM�TW!dw11btl"i!fflOfl : (£\·of5-Di�th)if�tilbenEt4-4'..Jtoi. mation in the intestinal mucosa and liver to its active powder. It is odourless. Practically insoluble in water; · metabolite 3-keto-desogestrel (-see soluble in alcohol, in acetone, in ether, in methyl alcohol, in C,aH,2qO�=iZ6�4 · p. 2277.3). propylene glycol, and in solutions of alkali hydroxides; <:)\��S6-_1�- t.· ATC:c References. slightly soluble in chloroform and in fatty oils. GOJC8(12;L02AA0 i, • ...... , . AI(,; Yit'7 ()(j03Cf!(J2; CXi03(C05, 1. Madden S, et al. Metabolism of the contraceptive desogestre] by . OL02Aj,p. l the intestinal mucosa. Br J Clin Phannacol 1989; 27: 295-9. .t;JN/1. -;''73}/JCAJ)B'[, . 2. Madden S, et a!. Metabolism of the contraceptive steroid desogestrel by Pharmaco oeias. In Chin., Bur. (see p. vii), and US. human liver . J Steroid Biochem 1990; 35: 281-8. Dienestrol is a synthetic oestrogen structurally p 3. Kuhnz W, et al. Protein binding of the contraceptive , Ph. Eur. 8: (Diethylstilbestrol). A white or almost white 3-keto·desogestrel and ethinyloestradiol in human serum. J Steroid related to diethylstilbestrol (below). It has been used as a Biochem 1990; 35: 313-18. vaginal cream in the treatment of menopausal atrophic crystalline powder. Practically insoluble in water; freely 4. Kuhnz W, et al. Pharmacokinetics and serum protein binding of 3-keto­ . If used on a long-term basis in women with a soluble in alcohol; dissolves in solutions of alkali desogestrel in women during three cycles of treatment with a low-dose uterus a progestogen is required. hydroxides. Protect from light. combination oral contraceptive. Arzneimittelforschung 1992; 42: 1142-6. 5. Timmer CJ, et al. and bioequivalence of etonogestrel from Dienestrol diacetate has been used as an ingredient of USP 36: (Diethylstilbestrol). A white, odourless, crystalline two oral formulations of desogestrel: Cerazette and liseta. Bur .J Drug topical preparations for skin disorders. powder. Practically insoluble in water; soluble in alcohol, in Metab Phannacokinet 1999; 24: 335-43. chloroform, in ether, in fatty oils, and in dilute alkali 6. Verhoeven CH, et al. and metabolism of desogestrel in healthy hydroxides. Store in airtight containers. Protect from light. postmenopausal women. J Steroid Biochem Mol Bioi 2001; 78: 471-80. P.r�P.?.r<:lti?.n.� 7. Korhonen T, et a!. The role of CYP2C and CYP3A in the disposition of 3- ProprietaryPreparations (details are given in Volume B) keto-desogestrel after administration of desogestrel. Br J Clin Phannacol Diethylstilbestrol Dipropionate (BANM, riNNM! 2005; 60: 69-75. Single-ingredient Prepara�ons. USA: Ortho-Dienestrolt. Pharmacopoeial Preparations USP 36: Dienestrol Cream. ProprietaryPreparations (details are given in Volume B) Single-ingredient Preparations. Arg.: Camelia; Carmin; Ceraz­ ette; Lumilac; Austria: Cerazette; Belg.: Cerazette; Lueva; Dienogest (BAN, USAN, r/NN) Braz. : Cerazette; Kelly; Chile: Arlette; Cerazette; Lactafem; Nogesta; Vanish; Cz.: Azalia; Cerazette; Fleur; Denm.: Cerazet; D\i; DlenulJ'!'�q�i sT5,s$7: A;teRorea: Cerazette; Nacrez; Fin.: Cerazette; Fr.: Cerazette; Ger.: Ceraz- r7'Hydr�xy-3-wo.'l9crtO,t:1.7o-pr�gflil-4,9,diene-2l:nitrile,

The symbol t denotes a preparation no longer actively marketed The symbol ® denotes a substance whose use may be restricted in certain sports (see p. viii)